Elderly Infection, Frailty, Frail Elderly Syndrome, Infection, Bacterial
Conditions
Keywords
amoxicillin, piperacillin-tazobactam, temocillin, pharmacokinetics, pharmacodynamics
Brief summary
In this pilot study, we will investigate whether - with the current dosing regimens, used in the Ghent University Hospital - pharmacodynamic targets regarding beta-lactam antibiotics (more specific Amoxicilline-Clavulanate, Piperacillin-Tazobactam and Temocillin) are attained in frail patients admitted to the geriatric department.
Detailed description
In drug research studies, older people - and especially patients with a geriatric profile or frailty risk - are very frequently excluded. Moreover, drug dosing is often extrapolated from studies in younger adults with failure to consider potential differences in pharmacokinetics (PK) and pharmacodynamics (PD). Studies on dosing of beta-lactam antibiotics in geriatric or frail patients aged 75 years or older have, to the best of our knowledge, never been performed. In this pilot study, we will investigate whether - with the current dosing regimens, used in the Ghent University Hospital - pharmacodynamic targets regarding beta-lactam antibiotics (more specific Amoxicilline-Clavulanate, Piperacillin-Tazobactam and Temocillin) are attained in frail patients admitted to the geriatric department. This monocentric, prospective, observational trial is currently ongoing at the emergency department and geriatric department of the Ghent University Hospital. Amoxicillin/clavulanic acid 1000/200mg of piperacillin-tazobactam 4000mg or temocillin 2000mg was infused intravenously over 30 minutes using a syringe pump. The standard dosing regimes were used. An infusion catheter of minimum 18-gauge was placed in the contralateral arm to the arm in which the antibiotic dose was administered. Blood samples were collected from this catheter at first dose and assumed steady state conditions. Steady state was assumed to be reached after minimal 24h (\> 4 doses at four - six hourly interval) of therapy. The goal was to obtain 5 first dose and 5 steady dose samples in every patient. Material for bacteriological analysis, such as blood cultures, urine samples, sputum, were collected in every patient according to standard care. In case of bacterial growth, MIC's were measured on the reported strains when possible. Amoxicillin, clavulanic acid, piperacillin, tazobactam and temocillin were measured using a validated ultra-performance liquid chromatographic method with tandem mass spectrometric detection. Serum creatinine, cystatin C, procalcitonin, infection parameters (CRP, WBC count) and albumin were obtained from standard blood samples performed in these patients at day one and also later on during their therapy. Three frailty score systems (KATZ, Geriatric 8 - G8, Cumulative Illness Rating Scale - CIRS) were calculated.
Interventions
DIAGNOSTIC_TESTBlood sampling
At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient. A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment. Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g. Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day).
DIAGNOSTIC_TESTSputum sample
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
DIAGNOSTIC_TESTHemoculture
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
DIAGNOSTIC_TESTUrine sample
Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
Sponsors
University Hospital, Ghent
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients presenting at the emergency department and later on admitted to the geriatric department * Patient age 75 years or older * Patients with geriatric profile according to KATZ scale, G8 screening test or CIRS score. * Patient receiving antibiotic treatment (amoxicillin-clavulanate, piperacillin-tazobactam) * Intravenous access available for blood sampling. For measurement of the peak concentration an intravenous access other than the drug infusion line is required.
Exclusion criteria
* Admission to other units than the geriatric department incl. the ICU. * Absence of informed consent * Known hypersensitivity to beta-lactam antibiotics * Patients who received oral amoxicillin-clavulanate prior to admission will not be included in the iv. amoxicillin-clavulanate group.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood concentrations of amoxicillin-clavulanate. | Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state) | To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions. |
| Blood concentrations of piperacillin-tazobactam. | Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state) | To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions. |
| Blood concentrations of temocillin. | Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state) | To investigate whether blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens in first-dose or early-dose conditions and in steady-state conditions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measured total and unbound concentrations of beta-lactam antibiotics. | Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state) | To compare measured total and unbound concentrations of beta-lactam antibiotics with predefined pharmacodynamic targets. |
| Clearance of betalactam antibiotics. | Within the first 12 hours (early dose) of treatment and after 24 - 48 hours of treatment (steady state) | To compare clearance of betalactam antibiotics and correlate with renal function using creatinin clearance en cystatin C. |
| Response to antimicrobial therapy. | The end of individual antibiotic therapy with an average of 1 week | To describe therapeutic response to antimicrobial therapy using procalcitonin. |
| Achievement of pharmacodynamic targets measured by questionnaire, vital signs, blood results and side effects. | The end of individual antibiotic therapy with an average of 1 week | To compare achievement of pharmacodynamic targets in early-dose and steady-state conditions. |
Countries
Belgium
Contacts
Primary ContactPeter De Paepe, Prof. Dr.
Backup ContactTania Desmet, Dr.
Outcome results
None listed